Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

Phase 1

Completed

Conditions: Dyslipidemia

Interventions: Drug: CKD-519
Drug: Placebo

First Posted Date: 2017-07-07

Last Posted Date: 2017-07-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 18

Registration Number: NCT03210649

Locations: 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of

A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects

Phase 1

Completed

Conditions: GERD

Interventions: Drug: CKD-381
Drug: Nexium

First Posted Date: 2017-07-07

Last Posted Date: 2017-11-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 41

Registration Number: NCT03211143

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

Phase 1

Completed

Conditions: Dyslipidemias

Interventions: Drug: Rosuvastatin 20 mg
Drug: CKD-519 200 mg
Drug: Rosuvastatin 20 mg & CKD-519 200 mg

First Posted Date: 2017-06-05

Last Posted Date: 2017-07-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT03175835

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Phase 1

Conditions: Myeloma, Multiple

Interventions: Drug: Treat Regimen

First Posted Date: 2017-05-12

Last Posted Date: 2020-02-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 18

Registration Number: NCT03150316

Locations: 🇰🇷
Samsung Hospital, Seoul, Gangnam-gu, Korea, Republic of
🇰🇷
the catholic university of korea, Seoul ST. Mary's Hospital, Seoul, Seocho, Korea, Republic of

A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.

Phase 1

Conditions: Colorectal Cancer

Interventions: Drug: CKD-516 Tablet

First Posted Date: 2017-03-10

Last Posted Date: 2017-03-10

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT03076957

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients

Phase 4

Completed

Conditions: Osteoarthritis Hand

Interventions: Drug: Celecoxib 100 MG
Drug: Celecoxib 200mg

First Posted Date: 2017-03-01

Last Posted Date: 2020-01-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 117

Registration Number: NCT03067194

Locations: 🇰🇷
Soon Chun Hyang University Hospital, Seoul, Korea, Republic of

Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily

Phase 2

Conditions: Glaucoma, Primary Open Angle
Ocular Hypertension

Interventions: Drug: D565H(Latanoprost 25㎍/㎖)
Drug: D565(Latanoprost 50㎍/㎖)

First Posted Date: 2017-03-01

Last Posted Date: 2017-07-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 98

Registration Number: NCT03067415

Locations: 🇰🇷
Seoul National University Hosipital, Seoul, Jongno, Korea, Republic of

Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure

Conditions: Essential Hypertension
Chronic Stable Angina
Congestive Heart Failure

First Posted Date: 2017-02-24

Last Posted Date: 2017-02-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 20000

Registration Number: NCT03063697

CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

Phase 1

Conditions: Myeloma, Multiple

Interventions: Drug: CKD-581

First Posted Date: 2017-02-14

Last Posted Date: 2020-02-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 18

Registration Number: NCT03051841

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

The Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: D930, D565

First Posted Date: 2017-01-27

Last Posted Date: 2017-07-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 15

Registration Number: NCT03034486

Locations: 🇰🇷
Dong-A University Hospital, Seo-gu, Busan, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy